Trial · NCT07378046
The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster
NCT07378046, Not applicable, Recruiting, Beijing Tiantan Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster. Trials, record NCT07378046. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07378046
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster
- NCT number
- NCT07378046
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 750 participants, estimated
- Lead sponsor
- Beijing Tiantan Hospital
- Conditions
- Herpes Zoster, Pain
- Interventions
- Baclofen combined conventional therapy, Conventional therapy
- First posted
- 2026-01-30
- Last updated
- 2026-01-30
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the average numeric rating scale score over the past 24 hours, rated each morning upon awakening and average over 7 days. | At week 4 after experimental drug medication | The numeric rating scale (NRS) score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain. A higher score indicates more severe pain. |
| Secondary | The worst numeric rating scale score | at weeks 1, 2, 4, 8, and 12 after experimental drug medication | The numeric rating scale (NRS) score is a way to quantify the degree of subjective feelings such as pain using numbers. Generally, 0 represents no pain, and 10 represents the most severe pain. A higher score indicates more severe pain. |
| Secondary | Proportion of Patients Achieving Pain Reduction | at weeks 1, 2, 4, 8, and 12 after experimental drug medication | The proportion of patients achieving a ≥ 50% and ≥ 30% reduction in mean baseline pain intensity |
| Secondary | Proportion of patients developing postherpetic neuralgia | at week 12 after experimental drug medication | |
| Secondary | The type of analgesics and average weekly consumption per analgesics | at weeks 4, 8, and 12 after experimental drug medication | |
| Secondary | The 12-item Short-Form Health Survey (SF-12) score | at weeks 4, 8, and 12 after experimental drug medication | The SF-12 score assesses the health-related quality of life, capturing preferences across various health states. It assesses 8 dimensions: physical functioning, physical role limitations due to physical health, bodily pain, general health, vitality, social functioning, emotional role limitations due to emotional problems, and mental health. Scores range from 0 to 100 for each dimension, with higher scores indicating better health status. |
| Secondary | The Medical Outcomes Study Sleep Scale (MOS) | at weeks 4, 8, and 12 after experimental drug medication | The MOS is a questionnaire comprising 12 items that assess various aspects of sleep using a 6-point ordinal scale (1 indicating permanence and 6 indicating absence). |
| Secondary | Adverse events | Through study completion, an average of 12 weeks | The incidence and proportion of adverse events will be recorded and categorized as mild, moderate, severe, or life-threatening. AEs are defined as events that arise during treatment, were absent before treatment, or worsen relative to the pretreatment state. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07378046
GET https://conductscience.org/api/trials/v1/NCT07378046/registered